<DOC>
	<DOCNO>NCT01332071</DOCNO>
	<brief_summary>The study prospective , open-label , randomize , crossover , 02 treatment , 02 sequence , 02 period . The volunteer receive , period , reference test formulation standardize meal .</brief_summary>
	<brief_title>Avandamet Bioequivalence Study Brazil - Fed Administration</brief_title>
	<detailed_description>This open-label , randomize , crossover study 02 treatment , 02 sequence , 02 period , healthy volunteer receive , period , test reference formulation standardize meal . Test product Rosiglitazone Maleate + Metformin - Avandamet 4 mg + 1000 mg ( GlaxoSmithKline Brasil Ltda ) form film coat tablet . Reference product Rosiglitazone Maleate + Metformin - Avandamet 2 mg + 500 mg ( Glaxo Smith Kline Brasil Ltda ) form film coat tablet . The population compose 26 healthy volunteer , adult , gender age vary 18 50 year . Their body mass index ( BMI ) vary 18,5 25 . There restriction regard ethnic group . The relative bioavailability two formulation , oral administration , evaluate base statistical comparison relevant pharmacokinetic parameter obtain data drug concentration blood .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>EXCLUSION CRITERIA : The volunteer know hypersensitivity study drug compound chemically relate ; History presence hepatic gastrointestinal illness , condition interferes drug 's absorption , distribution , excretion metabolism ; History neurological , endocrine , pulmonary , hamatologic , immune , brain , metabolic cardiovascular illness ; Hypo hypertension etiologic need pharmacologic treatment ; The result laboratory exams value consider normal accord protocol 's rule , unless consider clinically irrelevant investigator ; Has history alcohol drug abuse ; History use drug inducing and/or inhibitor hepatic metabolism within 30 day prior drug study administration ; Use MAO inhibitor two week start treatment ; Use inhibitor 5TH reuptake , Pregnancy breastfeeding , Smoking ; Use regular medication within 4 week prior study iniciation ; Use experimental drug participation clinical study within 6 month prior study iniciation . INCLUSION CRITERIA : Age 18 50 year ; Body mass index ≥ 18,5 ≤25,0 , vary 15 % upper limit ( 18,5 28,75 ) ; Good health condition ; Obtain Informed Consent 's sign .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Metformin</keyword>
	<keyword>Rosiglitazone</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Avandamet</keyword>
	<keyword>Fed condition</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>